{"id":"NCT01644474","sponsor":"Sanofi","briefTitle":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","officialTitle":"A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-07","completion":"2013-07","firstPosted":"2012-07-19","resultsPosted":"2015-11-06","lastUpdate":"2015-11-06"},"enrollment":103,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727"]},{"type":"DRUG","name":"Ezetimibe","otherNames":[]},{"type":"DRUG","name":"Placebo (for Alirocumab)","otherNames":[]},{"type":"DRUG","name":"Placebo (for Ezetimibe)","otherNames":[]}],"arms":[{"label":"Ezetimibe 10 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alirocumab 75/Up to 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).\n\nPrimary Objective of the study:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab in comparison with ezetimibe after 24 weeks of treatment in participants with hypercholesterolemia.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with ezetimibe on LDL-C at other time points\n* To evaluate the effect of alirocumab on other lipid parameters\n* To evaluate the safety and tolerability of alirocumab","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Ezetimibe 10 mg","deltaMin":-15.6,"sd":3.1},{"arm":"Alirocumab 75/Up to 150 mg Q2W","deltaMin":-47.2,"sd":3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":8,"countries":["United States","Belgium","Finland","Netherlands"]},"refs":{"pmids":["25037695","25606700","34298554","30183102","27777279"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":51},"commonTop":["Nasopharyngitis","Influenza","Diarrhoea","Upper respiratory tract infection","Nausea"]}}